微创医疗机器人 - 近期股价上涨限制上行空间，人工智能的应用效果尚待时间验证；维持中性评级

J P M O R G A N Asia Pacific Equity Research 06 March 2025 MicroPort MedBot Recent rally limiting upside, adoption of AI takes time to prove; remain Neutral Microport Medbot has outperformed the HSI by 100% in the past two months, driven by enthusiasm for AI and robotics stocks and progress in narrowing losses, with a breakeven target by 2026E. Recent profit alerts and order trends boost confidence in expanding its installation base, particularly overseas. Toumai is emerging as a value alternative to da Vin ...